Medicine
Inlyta 1 mg tablet
Inlyta 1 mg tablet is a prescription medicine containing Axitinib for oral use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Axitinib
- Brand
- Inlyta
- Strength
- 1 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 180 tablets
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories2 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01EK01 Axitinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 27 January 2012
- Identifiers
- RxCUI 1243004, 1243010, 1243012 +1DailyMed set ID 84137882-e000-47da-bd5b-fa76ab3c76f9, 8a903e31-936e-4ed7-8a59-59f32374f338NDC 0069-0145, 63539-026Application NDA202324
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 180 tablet, film coated in 1 bottle | 0069-0145-01 | Pfizer Laboratories | 27 January 2012 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Axitinib
Clinical summary
Axitinib is a kinase inhibitor indicated in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC), among other approved uses. It is available as tablets for oral use. MedsAcross supplies Axitinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AxitinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- INLYTA prescribing information (US Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Inlyta: European public assessment report (EPAR) · European Medicines Agency
- Axitinib Accord: European public assessment report (EPAR) · European Medicines Agency
Need Inlyta 1 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.